Clozapine-induced myocarditis, a widely overlooked adverse reaction

Acta Psychiatrica Scandinavica

Volumn 132, Issue 4, 2015, Pages 231-240

  Ronaldson, K J ^a   Fitzgerald, P B ^b   Mcneil, J J ^a  

^a MONASH UNIVERSITY   (Australia)

^b Monash University Central Clinical School and The Alfred Hospital ^*  (Australia)

Author keywords

Clozapine; Drug related side effects and adverse reactions; Incidence; Myocarditis

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

AUSTRALIA; DIAGNOSTIC ERROR; DRUG WITHDRAWAL; FATALITY; FEVER; HEART MUSCLE; HISTOPATHOLOGY; HUMAN; INCIDENCE; INVESTIGATIVE PROCEDURES; MEDLINE; MYOCARDITIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SUDDEN DEATH; ADOLESCENT; ADULT; AGED; CHEMICALLY INDUCED; EPIDEMIOLOGY; FEMALE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CLOZAPINE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDITIS; RISK FACTORS; YOUNG ADULT;

EID: 84941742118     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12416     Document Type: Review

References (92)

1. Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med 2005;353:1286-1288.
2. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
3. Fakra E, Azorin JM. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother 2012;13:1923-1935.
4. Vesterby A, Pedersen JH, Kaempe B, Thomsen NJ. Sudden death during treatment with clozapine (Leponex). Ugeskr Laeger 1980;142:170-171.
5. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-1845.
6. Haas SJ, Hill R, Krum H et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57.
7. Merrill DB, Ahmari SE, Bradford J-ME, Lieberman JA. Myocarditis during clozapine treatment. Am J Psychiatry 2006;163:204-208.
8. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005;25:32-41.
9. Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 2008;121:68-74.
10. Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012;73:1307-1312.
11. Reinders J, Parsonage W, Lange D, Potter JM, Plever S. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004;38:915-922.
12. Beier J, Haastrup S. ECG changes developing during clozapine treatment. Ugeskr Laeger 1985;147:619-620.
13. Juul Povlsen U, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185.
14. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524-529.
15. Meeker JE, Herrmann PW, Som CW, Reynolds PC. Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol 1992;16:54-56.
16. Jensen VE, Gotzsche O. Allergic myocarditis in clozapine treatment. Ugeskr Laeger 1994;156:4151-4152.
17. Lilleng P, Morild I, Hope M. Clozapine and myocarditis. Tidsskr Nor Laegeforen 1995;115:3026-3027.
18. Bandelow B, Degner D, Kreusch U, Ruther E. Myocarditis under therapy with clozapine. Schizophr Res 1995;17:293-294.
19. Khalil N. Peri-/myocarditis with clozapine (Leponex). Psychiatr Prax 1997;24:46.
20. Kirpekar VC, Deshpande SM, Joshi PP. Reversible myocarditis in a patient receiving clozapine. Indian Heart J 2001;53:779-781.
21. Reid P. Clozapine rechallenge after myocarditis. Aust N Z J Psychiatry 2001;35:249.
22. Kay SE, Doery J, Sholl D. Clozapine associated pericarditis and elevated troponin I. Aust N Z J Psychiatry 2002;36:143-144.
23. Phan KL, Taylor SF. Clozapine-associated cardiomyopathy. Psychosomatics 2002;43:248.
24. Fineschi V, Neri M, Riezzo I, Turillazzi E. Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. Int J Legal Med 2004;118:307-309.
25. Pieroni M, Cavallaro R, Chimenti C, Smeraldi E, Frustaci A. Clozapine-induced hypersensitivity myocarditis. Chest 2004;126:1703-1705.
26. Razminia M, Salem Y, Devaki S, Shah N, Khosla S. Clozapine induced myopericarditis: early recognition improves clinical outcome. Am J Ther 2006;13:274-276.
27. Kakar P, Millar-Craig M, Kamaruddin H, Burn S, Loganathan S. Clozapine induced myocarditis: a rare but fatal complication. Int J Cardiol 2006;112:e5-e6.
28. Tirupati S. Clozapine and heart in the Hunter region. Aust N Z J Psychiatry 2006;40:97.
29. Martinez Rey C, Villamil Cajoto I, Rodriguez Framil M, Tome Martinez De Rituerto S, Torre Carballada JA. Myocarditis from clozapine. An Med Interna 2006;23:503-504.
30. Varambally S, Howpage P. Acute myocarditis associated with clozapine. Australas Psychiatry 2007;15:343-346.
31. Belloni E, de Cobelli F, Esposito A et al. Myocarditis associated with clozapine studied by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2007;9:591-593.
32. Annamraju S, Sheitman B, Saik S, Stephenson A. Early recognition of clozapine-induced myocarditis. J Clin Psychopharmacol 2007;27:479-483.
33. Lang UE, Willbring M, Von Golitschek R, Schmeisser A, Matschke K, Malte Tugtekin S. Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. J Psychopharmacol (Oxf) 2008;22:576-580.
34. Caetano D, Gandhi C. Clozapine-induced myocarditis. Aust N Z J Psychiatry 2008;42:434-435.
35. Caetano D. Monitoring of clozapine-induced myocarditis. Australas Psychiatry 2009;17:421.
36. Jayathilake I, Singh AK. Clozapine rechallenge after myocarditis. Australas Psychiatry 2009;17:421-422.
37. Ariyarajah V, Shaikh N, Garber PJ, Kirkpatrick I, McGregor R, Jassal DS. Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities? J Magn Reson Imaging 2010;31:1473-1476.
38. O'connor DW, Sierakowski C, Chin LF, Singh D. The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J Biol Psychiatry 2010;11:788-791.
39. Rosenfeld AJ, Gibbs T, Ivie R, Clarke L, Merrill DB. Successful clozapine retrial after suspected myocarditis. Am J Psychiatry 2010;167:350-351.
40. Crews MP, Dhillon GS, MacCabe JH. Clozapine rechallenge following clozapine-induced pericarditis. J Clin Psychiatry 2010;71:959-961.
41. Grgas M, Washburn CF Jr, Caley CF. Clozapine-induced myocarditis: 2 case reports. J Clin Psychopharmacol 2010;30:91-92.
42. Hassan I, Brennan A, Carroll A, Dolan M. Monitoring in clozapine rechallenge after myocarditis. Australas Psychiatry 2011;19:370-371.
43. Bray A, Reid R. Successful clozapine rechallenge after acute myocarditis. Aust NZ J Psychiatry 2011;45:90.
44. Power B, Williams H, Shymko G. The difficulties of diagnosing clozapine myocarditis: damned if you do, damned if you don't. Australas Psychiatry 2012;20:165-166.
45. Albouaini K, Ruzsics B, Chenzbraun A. Multimodality cardiac imaging in Clozapine-induced eosinophilic constrictive perimyocarditis. Eur Heart J Cardiovasc Imaging 2013;14:338.
46. Granja-Ingram NM, James J, Clark N, Stovall J, Heckers S. Successful re-exposure to clozapine after eosinophilia and clinically suspected myocarditis. Rev Bras Psiquiatr 2013;35:95-96.
47. Aldridge G, Collins C, Croucher M. Clozapine-induced pneumonitis. Aust N Z J Psychiatry 2013;47:1215-1216.
48. Kikuchi Y, Ataka K, Yagisawa K et al. Clozapine-induced cardiomyopathy: a first case in Japan. Schizophr Res 2013;150:586-587.
49. Chow V, Feijo I, Trieu J, Starling J, Kritharides L. Successful rechallenge of clozapine therapy following previous clozapine-induced myocarditis confirmed on cardiac MRI. J Child Adolesc Psychopharmacol 2014;24:99-101.
50. Munshi TA, Volochniouk D, Hassan T, Mazhar N. Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition? Case Rep Psychiatry 2014;2014:513108.
51. Committee on Safety of Medicines. Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). Curr Prob Pharmacovigil 1993;19:9-10. Internet: http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON2024456&RevisionSelectionMethod=LatestReleased (Accessed 8 Oct 2013).
52. Degner D, Bleich S, Grohmann R, Bandelow B, Ruther E. Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry 2000;34:880.
53. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21:382-388.
54. la Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345:224-225.
55. Wooltorton E. Antipsychotic clozapine (Clozaril): Myocarditis and cardiovascular toxicity. Can Med Assoc J 2002;166:1185-1186.
56. Murch S, Tran N, Liew D, Petrakis M, Prior D, Castle D. Echocardiographic monitoring for clozapine cardiac toxicity: lessons from real-world experience. Australas Psychiatry 2013;21:258-261.
57. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322:1207-1209.
58. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine induced myocarditis based on an analysis of 75 cases and 94 controls. Aust NZ J Psychiatry 2011;45:458-465.
59. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, McNeil JJ. Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011;128:161-165.
60. Devarajan S, Kutcher SP, Dursun SM. Clozapine and sudden death. Lancet 2000;355:841.
61. Wehmeier PM, Heiser P, Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther 2005;30:91-96.
62. Wehmeier PM, Schuler-Springorum M, Heiser P, Remschmidt H. Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. J Child Adolesc Psychopharmacol 2004;14:267-271.
63. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012;141:173-178.
64. Novartis Pharmaceuticals Australia Pty Ltd. Clozaril (clozapine) Product Information, Australia (26 Aug 2014): https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-00043-3 (Accessed 16 Oct 2014).
65. Novartis Pharmaceuticals Corporation. Clozaril (clozapine) Label, USA (29 Sep 2014): http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019758s072lbl.pdf (Accessed 16 Oct 2014).
66. Novartis Pharmaceuticals UK Limited. Clozaril (clozapine) Summary of Product characteristics, United Kingdom (14 Apr 2014): http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1410501563443.pdf (Accessed 16 Oct 2014).
67. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677.
68. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psych 2010;71:976-981.
69. Lambert TJR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178:S67-S70.
70. Ronaldson KJ, Fitzgerald PB, Taylor AJ, McNeil JJ. Continuation of clozapine following mild myocarditis. Aust N Z J Psychiatry 2012;46:910-911.
71. Chung JP, Chong CS, Chung K, Dunn EL, Wai-Nang Tang OW, Chan W. The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008;53:857-862.
72. Tham JC, Dickson RA. Clozapine-induced fevers and 1-year clozapine discontinuation rate. J Clin Psych 2002;63:880-884.
73. Gaertner HJ, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology 1989;99(Suppl):S97-S100.
74. Jeong S-H, Ahn Y-M, Koo Y-J, Kang UG, Kim YS. The characteristics of clozapine-induced fever. Schizophr Res 2002;56:191-193.
75. Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia-a retrospective study of 387 patients. Psychopharmacology 1989;99(Suppl):S73-S76.
76. Patterson BD, Jennings JL. Spiking fever and profuse diarrhea with clozapine treatment. Am J Psychiatry 1993;150:1126.
77. Tremeau F, Clark SC, Printz D, Kegeles LS, Malaspina D. Spiking fevers with clozapine treatment. Clin Neuropharmacol 1997;20:168-170.
78. Kohen I, Afzal N, Hussain S, Manu P. Increases in C-reactive protein may predict recurrence of clozapine-induced fever. Ann Pharmacother 2009;43:143-146.
79. Martin N, Williams R. Management of clozapine-induced fever: a case of continued therapy throughout fever. J Psychiatry Neurosci 2013;38:E9-E10.
80. Štuhec M. Clozapine-induced elevated C-reactive protein and fever mimic infection. Gen Hosp Psychiatry 2013;35:680. e5-6.
81. Driver DI, Anvari AA, Peroutka CM et al. Management of clozapine-induced fever in a child. Am J Psychiatry 2014;171:398-402.
82. Nitenson NC, Kando JC, Frankenburg FR, Zanarini MC. Fever associated with clozapine administration. Am J Psychiatry 1995;152:1102.
83. Pai NB, Vella SC. Reason for clozapine cessation. Acta Psychiatr Scand 2012;125:39-44.
84. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-127.
85. Ray WA, Chung CP, Murray KT, Hall K, Stein MC. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-235.
86. Rosh A, Sampson BA, Hirsch CS. Schizophrenia as a cause of death. J Forensic Sci 2003;48:164-167.
87. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343:1388-1398.
88. de Berardis D, Serroni N, Campanella D et al. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 2012;7:55-62.
89. Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry 2009;194:165-167.
90. Kelly DL, Wehring HJ, Linthicum J et al. Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophr Res 2009;107:134-138.
91. Flanagan RJ, Spencer EP, Morgan PE, Barnes TRE, Dunk L. Suspected clozapine poisoning in the UK/Eire, 1992-2003. Forensic Sci Int 2005;155:91-99.
92. Kuo C, Yang SY, Liao YT et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013;39:648-657.